Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Inflammation a key to targeting pregnancy-associated breast cancer
(Garvan Institute of Medical Research) Targeting the tumour environment may help improve treatments for breast cancers affecting pregnant women and young mothers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 13, 2021 Category: Cancer & Oncology Source Type: news

Propylparaben exposure during pregnancy may reduce protection against breast cancer
(The Endocrine Society) Low doses of propylparaben--an estrogen-like chemical used as a preservative in personal care products and foods--can alter pregnancy-related changes in the breast in ways that may reduce the normal protection against breast cancer that pregnancy hormones convey, according to a new study being published in the Endocrine Society's journalEndocrinology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 16, 2021 Category: Cancer & Oncology Source Type: news

Exposure to common chemical during pregnancy may reduce protection against breast cancer
(University of Massachusetts Amherst) Low doses of propylparaben - a chemical preservative found in food, drugs and cosmetics - can alter pregnancy-related changes in the breast in ways that may lessen the protection against breast cancer that pregnancy hormones normally convey, according to University of Massachusetts Amherst research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 16, 2021 Category: Cancer & Oncology Source Type: news

Cochrane community participates in a virtual walk to raise money for Anne Anderson Award
The global Cochrane community are walking andraising money for the annual Anne Anderson Award, which is given to a Cochrane member who has contributed meaningfully to the promotion of women as leaders and contributors to the organization.Given we can't meet in-person for our 2021 Anne Anderson Walk, we are doing it virtually. Participants are making donations and sharing pictures themselves on their walk or their local area - click on the map below to see!  Who is Anne Anderson?Anne Anderson was a contributor to the stream of thinking and effort that gave birth to evidence-based health care. A clinically qualified rep...
Source: Cochrane News and Events - February 25, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

International Women's Day Panel on diversity in health evidence synthesis
On International Women's Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis.  Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Anne Anderson Walk'at the Cochrane Colloquium to rais...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

VIDEO: International Women's Day Panel on diversity in health evidence synthesis
On International Women's Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis.  Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Anne Anderson Walk'at the Cochrane Colloquium to rais...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

International Women's Day Panel on diversity in health evidence synthesis - 8 March 2021
International Women's Day is March 8th!  Join us as we discuss and highlight minority women and young investigators working in health science and evidence synthesis. Hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Ann Anderson Walk'at the Cochrane Colloquium to raise money for...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Pregnancy After Breast Cancer Doesn't Increase Recurrence Risk Pregnancy After Breast Cancer Doesn't Increase Recurrence Risk
Among women who became pregnant, breast cancer survivors did not have higher odds of miscarriage or complications like preeclampsia, and their babies were not more likely to have congenital abnormalities.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

SABCS: Pregnancy Less Likely After Breast Cancer Diagnosis
Disease - free, overall survival better for breast cancer patients with versus without subsequent pregnancy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 14, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Conference News, Source Type: news

SABCS: Pregnancy Less Likely After Breast Cancer Diagnosis
MONDAY, Dec. 14, 2020 -- Pregnancy is less likely after prior breast cancer (BC) diagnosis, according to the results of a review presented at the annual San Antonio Breast Cancer Symposium, held virtually from Dec. 8 to 11. Eva Blondeaux, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2020 Category: Pharmaceuticals Source Type: news

Pregnancy is safe for breast cancer survivors
Most breast cancer survivors who get pregnant have good outcomes and deliver...Read more on AuntMinnie.comRelated Reading: Skipping rad therapy may not hinder breast cancer survival Imaging detects big, rare tumor protruding from fetus's mouth Ultrasound vs. mammo: What's best for lactating women? CT details effect of COVID-19 on pregnant women More pregnant women are undergoing imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 10, 2020 Category: Radiology Source Type: news

Second opinion changed breast cancer treatment, preserved fertility
Everyone ’s breasts get lumpy when they’re nursing a newborn, right? That’s what Leslie McGuire, age 30, thought to herself in 2014. “Breastfeeding wasn’t easy for me, and I had a lot of breast changes after my pregnancy, so when I felt a lump, I just assumed it must be related to that,” says t he Kansas City, Missouri, resident. But with an extensive family history of breast and ovarian cancers, McGuire was concerned when the lump didn’t disappear after she stopped nursing. She thought… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 1, 2020 Category: Pharmaceuticals Authors: The University of Kansas Health System Source Type: news

Pregnancy Outcomes Excellent After BRCA Breast Cancer Treatment Pregnancy Outcomes Excellent After BRCA Breast Cancer Treatment
Pregnancy after treatment for breast cancer with BRCA mutations is safe, with excellent fetal outcomes and no increase in cancer recurrence, say researchers reporting a review of more than 1000 women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Micro-CT visualizes early fetal development
Dutch researchers have released images acquired using micro-CT that depict...Read more on AuntMinnie.comRelated Reading: Contrast MRI helps radiologists identify ectopic pregnancy 3D micro-CT primed to revamp breast cancer imaging Micro-CT unveils curious history of ancient manikins Micro-CT detects early tumor growth in lymph nodes Micro-CT reveals hawk mummy is actually a human fetus (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 13, 2020 Category: Radiology Source Type: news

Pregnancy reprograms breast cells, reducing cancer risk
(Cold Spring Harbor Laboratory) Women who are pregnant before the age of 25 have a decreased risk of breast cancer throughout their lives. Searching for the mechanism behind this life-saver, CSHL researchers discovered that pregnancy reprograms the breast cells to turn off a cancer gene and turn on a gene that arrests cell growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 27, 2020 Category: Cancer & Oncology Source Type: news

ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® ...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rise in breast cancer fueled by more than later pregnancy, lower birth rate
Rising breast cancer rates in the U.S. during the last 40 years have long been linked with women opting to have children later in life, if at all. An analysis published Friday, however, challenges that idea. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 13, 2020 Category: Consumer Health News Source Type: news

Mother diagnosed with breast cancer during pregnancy feared she would lose her baby
Kirsty Guy, 30, from Ellesmere Port, Cheshire, assumed a lump in her right breast was a symptom of her pregnancy and claims she was reassured by her GP. (Source: the Mail online | Health)
Source: the Mail online | Health - March 2, 2020 Category: Consumer Health News Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Combining neurologic and blood pressure drugs reduces breast tumor development in mice
(Georgetown University Medical Center) Adding a medication used to treat epilepsy, bipolar disorder and migraines to a blood pressure medicine reversed some aspects of breast cancer in the offspring of mice at high risk of the disease because of the high fat diet fed to their mothers during pregnancy. Conversely, this treatment combination increased breast cancer development in the offspring whose mothers had not been fed a high fat diet during pregnancy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 30, 2019 Category: International Medicine & Public Health Source Type: news

Saving lives, improving mother's care
This report, the sixth MBRRACE-UK annual report of the Confidential Enquiry into Maternal Deaths and Morbidity, includes: surveillance data on women who died during or up to one year after pregnancy between 2015 and 2017 in the UK; Confidential Enquiries into the care of women who died between 2015 and 2017 in the UK and the Republic of Ireland from cardiovascular causes, hypertensive disorders, early pregnancy conditions and accidents; a Morbidity Confidential Enquiry into the care of women with newly diagnosed breast cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 17, 2019 Category: Consumer Health News Source Type: news

Cancer patients want more info on treatment downside
One in three adults wish they had known more about side effects before beginning...Read more on AuntMinnie.comRelated Reading: Black women still at higher risk of breast cancer death ASTRO: Radiation can nix side effects of T-cell therapy ASTRO: AI predicts side effects from radiation therapy How does chemo during pregnancy affect child development? Advanced imaging offers insight into targeted therapies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 21, 2019 Category: Radiology Source Type: news

Woman who underwent chemotherapy for rare form of cancer during pregnancy kisses her 'miracle' baby
Jade Devis, 36, of Rancho Cucamonga, California, was diagnosed with stage 2 triple-negative breast cancer, a rare form of the disease, just a few months after learning that she was pregnant. (Source: the Mail online | Health)
Source: the Mail online | Health - October 28, 2019 Category: Consumer Health News Source Type: news

The Week That Wasn't: Viagra BMTs, Pregnancy Stress, Breast Cancer Vaccine The Week That Wasn't: Viagra BMTs, Pregnancy Stress, Breast Cancer Vaccine
Three medical stories that we didn't cover, explained.Medscape (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 18, 2019 Category: Internal Medicine Tags: Family Medicine/Primary Care Article Source Type: news

Africa: More Breastfeeding Could Save the World $1 Billion Every Day
[Thomson Reuters Foundation] Kuala Lumpur -Breastfeeding can help prevent diarrhea and pneumonia, two major causes of infant death, and protect mothers against ovarian and breast cancer (Source: AllAfrica News: Pregnancy and Childbirth)
Source: AllAfrica News: Pregnancy and Childbirth - July 18, 2019 Category: OBGYN Source Type: news

Beagles Diagnosing Cancer ‘Could Work with Mesothelioma’
Specially trained beagles could one day detect mesothelioma by scent, according to the lead researcher of a recent study detailing the dog breed’s stunning accuracy with lung cancer. Dr. Thomas Quinn, clinical professor at the Lake Erie College of Osteopathic Medicine, believes the dogs could be equally effective with pleural mesothelioma, a rare cancer caused by asbestos exposure. “Absolutely, this could work with mesothelioma. There is no reason why it wouldn’t,” Quinn told The Mesothelioma Center at Asbestos.com. “That is another cancer with strong potential for this to work well.” Th...
Source: Asbestos and Mesothelioma News - July 10, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Is Pregnancy Safe Following Breast Cancer for Patients With a BRCA Mutation?
A large international study looked at whether pregnancy is safe after breast cancer for women who have a BRCA mutation. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news

Women Die From Heart Attacks More Often Than Men. Here ’s Why — and What Doctors Are Doing About It
Lilly Rocha was 37 years old in 2008 when she began having strange symptoms. When people asked her questions, she knew the answers but couldn’t articulate them. A tingling sensation on her left breast became painful. She thought she might have breast cancer, but her doctor assured her she was just experiencing stress from her demanding job. Her symptoms continued to get worse, and doctors continued to dismiss her. Three months later, at work, she became seriously ill. Luckily, her boss recognized the symptoms—chest and jaw pain and numbness in her left hand—and drove her to the nearest emergency room, whe...
Source: TIME: Health - April 1, 2019 Category: Consumer Health News Authors: Barbara Sadick Tags: Uncategorized heart health Source Type: news

Pregnancies Tied to Breast Cancer Odds for High-Risk Women Pregnancies Tied to Breast Cancer Odds for High-Risk Women
Having more than one pregnancy has long been linked to lower odds of breast cancer, and a new study suggests that may hold true even for some women with genetic mutations that put them at high risk for these malignancies.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pregnancies tied to breast cancer odds for high-risk women
(Reuters Health) - Having more than one pregnancy has long been linked to lower odds of breast cancer, and a new study suggests that may hold true even for some women with genetic mutations that put them at high risk for these malignancies. (Source: Reuters: Health)
Source: Reuters: Health - March 13, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Number and timing of pregnancies influence breast cancer risk for women with BRCA1 or BRCA2 mutation
(Columbia University's Mailman School of Public Health) Researchers confirm the lower risk of breast cancer from multiple pregnancies and from breast feeding seen in average risk women extends to those at the highest risk of breast cancer, according to the largest prospective study of BRCA1 and BRCA2 mutations carriers to date. Women with BRCA1 mutations who had two, three or four or more full-term pregnancies were at 21 percent, 30 percent, and 50 percent decrease risk of breast cancer compared to women with a single full-term pregnancy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 8, 2019 Category: Cancer & Oncology Source Type: news

Breast cancer risk remains elevated 20-30 years after childbirth
New research shows pregnancy first elevates breast cancer risk, but becomes protective over time. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - January 3, 2019 Category: Environmental Health Source Type: news

NIH scientists find that breast cancer protection from pregnancy starts decades later
Breast cancer risk remains elevated 20-30 years after childbirth. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 14, 2018 Category: American Health Source Type: news

NIH scientists find that breast cancer protection from pregnancy starts decades later
(NIH/National Institute of Environmental Health Sciences) In general, women who have had children have a lower risk of breast cancer compared to women who have never given birth. However, new research has found that moms don't experience this breast cancer protection until many years later and may face elevated risk for more than 20 years after their last pregnancy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 14, 2018 Category: Cancer & Oncology Source Type: news

Breast Cancer Risk May Rise After Childbirth, but Is Still Low
Women who recently gave birth may have an increased risk of breast cancer that lasts about 20 years. But for most, the overall risk is still small. (Source: NYT Health)
Source: NYT Health - December 13, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Breast Cancer Pregnancy and Childbirth Breasts Breastfeeding Annals of Internal Medicine Source Type: news

Risk for Breast Cancer Linked to Pregnancy History (CME/CE)
(MedPage Today) -- Large pooled analysis suggests parity may not be protective for women under age 55 (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2018 Category: Hematology Source Type: news

Breast Cancer Risk Tied to Pregnancy History
(MedPage Today) -- Pooled analysis suggests parity may not be protective for women under age 55 (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 10, 2018 Category: Hematology Source Type: news

Improved Long-Term Pregnancy Outcomes for Goserelin & #43; Chemo
THURSDAY, Nov. 8, 2018 -- For premenopausal women with stage I to IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer, goserelin plus chemotherapy is associated with an increased likelihood of becoming pregnant without an... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 8, 2018 Category: Pharmaceuticals Source Type: news

Sex hormone blocker increases likelihood of pregnancy in breast cancer patients
The sex hormone blocker, goserelin, protects the ovaries from breast cancer chemotherapy, improving the likelihood of future pregnancy, according to research published in theJournal of the National Cancer Institute. Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 31, 2018 Category: Endocrinology Source Type: news

Breast-Feeding Is Good for the Mother, and Not Just the Baby
Women who breast-feed are less likely to develop breast cancer, ovarian cancer, Type 2 diabetes and rheumatoid arthritis and may have improved cardiovascular health. (Source: NYT Health)
Source: NYT Health - October 26, 2018 Category: Consumer Health News Authors: RONI CARYN RABIN Tags: Breast Cancer Breastfeeding Women and Girls Ovarian Cancer Pregnancy and Childbirth Diabetes Babies and Infants Parenting Infant Formulas Source Type: news

While Pregnancy May Be Possible After Chemo, How Many Patients ’ Plans Change?
While becoming pregnant is generally possible for younger breast cancer patients, researchers believe many women change their minds after treatment. (Source: CancerNetwork)
Source: CancerNetwork - October 22, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Pregnancy possible after chemotherapy for breast cancer patients, but many no longer wish
(European Society for Medical Oncology) Chemotherapy is known to have a negative impact on the reproductive potential of young breast cancer patients. Its effects on women's post-treatment fertility, however, are still poorly understood. A study to be presented at the ESMO 2018 Congress in Munich, has confirmed that natural pregnancies are possible after chemotherapy but that survivors' desire to have children decreases greatly after treatment, calling into question the need for systematic recourse to fertility preservation measures. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 19, 2018 Category: Cancer & Oncology Source Type: news

Women treated for cancer have higher CHF risk in pregnancy
Anthracycline-exposed women should receive close cardiac surveillance during pregnancy Related items fromOnMedica Child cancer survivors can become pregnant as adults Breast cancer during pregnancy need not harm baby Include pregnant women in studies, urge researchers Heart failure with preserved ejection fraction (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 16, 2018 Category: UK Health Source Type: news

Would you trust a £200 scanner to check your breasts at home? Ground-breaking new gadgets developed
Over the past three years, boffins have been focusing on women’s health concerns, from fertility and contraceptives to breast cancer and pregnancy care. (Source: the Mail online | Health)
Source: the Mail online | Health - October 14, 2018 Category: Consumer Health News Source Type: news

RoomLab CEO: On Fighting Cancer, A Surprise Pregnancy And Raising Investment
“It was an enormous shock,” says Suzann Bozorgi after a deep breath. The entrepreneur is still new to talking about the breast cancer diagnosis that rocked her life. Yet her mental and physical experience of cancer have directly influenced her the two businesses she's founded. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 14, 2018 Category: Pharmaceuticals Authors: Kitty Knowles, Forbes Staff Source Type: news